Sleep Apnoea Treatment UK NHS: CPAP Alternatives in 2026

CPAP remains NHS first-line for moderate-severe obstructive sleep apnoea in the UK. 2026 alternatives include mandibular devices, positional therapy, GLP-1 weight loss with tirzepatide newly licensed for OSA, hypoglossal nerve stimulation at growing NHS centres, and selected surgery.

The scenario is common in UK households. One partner snores like a chainsaw, wakes with a gasp, and falls asleep at the wheel on the school run. They struggle through the day on coffee, blaming fatigue on a busy life. Or perhaps it’s a woman in her 50s, finally tested after a year of exhaustion dismissed as perimenopause, only to find a moderate apnoea-hypopnoea index (AHI) on her sleep study. Obstructive sleep apnoea (OSA) affects about 1.5 million UK adults, and up to 85 percent are undiagnosed. This article walks you through the NHS pathway in 2026—what to expect at the sleep clinic, why CPAP is still the first-line treatment, and why about a third of patients struggle with it. We’ll then explore the real-world alternatives now available in the UK: mandibular devices, positional therapy, GLP-1 weight loss medications like the newly licensed tirzepatide, hypoglossal nerve stimulation implants, and surgery for specific anatomical issues.

How obstructive sleep apnoea is diagnosed on the NHS in 2026

The journey typically starts with a partner’s observation or your own concern about unrefreshing sleep and daytime sleepiness. Your GP will ask about key symptoms: loud snoring, witnessed pauses in breathing, gasping or choking at night, excessive daytime sleepiness, morning headaches, low mood, and low libido. They’ll also consider risk factors like weight, neck circumference, and alcohol or sedative use.

A common first step is the Epworth Sleepiness Scale (ESS), an 8-question tool scored from 0 to 24. A score of 11 or above suggests significant daytime sleepiness; above 16 is severe. Your GP will then refer you to a regional sleep clinic, usually run by respiratory medicine or ENT. In some UK Integrated Care Boards in 2026, GPs can now directly order overnight home pulse oximetry, which speeds up the initial step.

Step two is usually a home pulse oximetry test—a finger probe you wear overnight and post back. Oxygen dips suggest apnoea events. This is free on the NHS. If results are confirmatory or unclear, the next step is a fuller home sleep study (cardiorespiratory polygraphy) or, in selected cases, an in-lab polysomnography. The diagnosis is confirmed by the apnoea-hypopnoea index (AHI): 5-14 is mild, 15-29 moderate, and 30 or above is severe. Your oxygen desaturation index and ESS score are also documented.

Finally, you’ll discuss treatment options. CPAP is the NHS first-line for moderate to severe OSA. Alternatives are considered for mild OSA, for selected patients, or when CPAP cannot be tolerated. Waiting times in 2026 vary from six weeks to nine months by trust, which leads many UK adults to pay £250-450 for a private home sleep study to skip the queue.

CPAP on the NHS: why it is still the gold standard

Continuous positive airway pressure (CPAP) remains the NHS cornerstone for treating moderate to severe OSA. It’s a small bedside machine that pushes pressurised air through tubing into a mask you wear overnight. This air pressure acts as a pneumatic splint, holding your airway open and stopping the apnoea events. The NHS provides the machine, mask, tubing, all follow-up care, and replacement parts free for life. Most NHS sleep services now use APAP (auto-titrating CPAP), which automatically adjusts the pressure throughout the night based on your needs.

When used properly, CPAP is highly effective. It reduces the AHI by 80-95 percent, reduces daytime sleepiness within two to four weeks, and improves blood pressure, cardiovascular risk markers, mood, and concentration. It often improves the bed partner’s sleep more than the patient’s.

The UK NHS reality, however, is that adherence is a challenge. About 60-70 percent of patients are still using CPAP at one year. Common difficulties include mask leaks, claustrophobia, dry nose or mouth, pressure intolerance, and the inconvenience of the hose. Many of these issues are fixable by your NHS sleep service: changing the mask type (from nasal pillows to a full-face mask), adding a heated humidifier, using the ramp feature to ease into pressure, or adjusting the pressure range. UK patients now often get usage data via NHS clinic portals and have remote reviews.

For travel, standard NHS CPAP machines work fine abroad with a simple plug adapter. Portable travel CPAPs (like the ResMed AirMini) are available privately for £600-900 but are not funded by the NHS. The bottom line is that CPAP changes lives when it works. Persevere through the first four to six weeks. The NHS sleep clinic is there to help fix the issues, not to give up on you.

Mandibular advancement devices (MADs)

A mandibular advancement device (MAD) is like a custom-fitted gum shield worn at night. It holds the lower jaw and tongue forward by 5-10 mm, opening the airway behind the tongue. In the UK, NHS availability is limited but growing in some regions (notably Wales, parts of Scotland, and via specific NHS England dental sleep medicine clinics). Access often requires a referral from the sleep clinic or maxillofacial team.

Most UK adults, however, access MADs privately through a dentist trained in dental sleep medicine. A custom appliance from brands like SomnoDent or Narval CC costs between £350 and £800. Over-the-counter ‘boil-and-bite’ devices (£50-150) are less effective and can cause tooth or jaw problems with prolonged use.

Evidence shows a custom MAD reduces AHI by 50-60 percent on average. While less effective than CPAP at reducing AHI numbers, it is often better tolerated. NICE supports MAD for mild OSA and as an alternative when CPAP is not tolerated. Recent 2025 systematic reviews show MAD is comparable to CPAP for symptom improvement in mild to moderate OSA.

The best candidates are non-obese patients with good dentition and mild to moderate OSA. It’s less suitable for severe OSA or where teeth are missing. Side effects like jaw tenderness or excess salivation usually settle within two to four weeks. A dental review every 12 months is recommended. For many, a custom MAD from a specialist dentist is the most practical and effective alternative.

Positional therapy: when sleeping on your side actually works

Positional OSA means your apnoea events are significantly worse when you sleep on your back. Technically, it’s defined as a supine AHI more than double your lateral AHI on a sleep study. Roughly 30-40 percent of UK OSA patients have a positional component.

For these patients, simple side-sleeping strategies can be surprisingly effective. The classic ‘tennis ball trick’—sewing a tennis ball into the back of your pyjamas—makes back-sleeping uncomfortable and is cheap and effective for many. Dedicated positional therapy belts and waistcoats (like Night Shift or Somnibel) use gentle vibration when you roll onto your back; these cost £100-250 and are sometimes lent by NHS clinics. Specialist side-sleeper pillows or wedge cushions can also help.

The evidence is solid for this group. 2024 Cochrane and 2025 reviews show a 50-70 percent reduction in supine sleep time and a 20-40 percent AHI reduction in proven positional OSA. It’s less effective than CPAP but very well tolerated and often combined with weight loss or a MAD.

The important step is to confirm positional OSA on your sleep study. Ask the sleep service to report your positional data. If the criteria are met, positional therapy is a worthwhile, low-cost intervention. It is not appropriate as a standalone treatment for severe, non-positional OSA.

Weight loss including tirzepatide for OSA (new UK licence 2025)

Obesity is the most modifiable cause of obstructive sleep apnoea. UK data is clear: a 10 percent body weight loss reduces AHI by about 25-30 percent. A more substantial loss of 20 percent or more can resolve mild to moderate OSA entirely in many patients. Weight loss alone rarely cures severe OSA but consistently makes CPAP work better.

UK weight management options in 2026 include NHS Tier 2 (community) and Tier 3 (specialist) services via GP referral. The biggest recent shift involves GLP-1 medications. Semaglutide (Wegovy for weight loss) and liraglutide (Saxenda) are available.

The major 2025 development is the UK MHRA approval of tirzepatide (Mounjaro) specifically for moderate to severe obstructive sleep apnoea in adults with obesity. This was based on the SURMOUNT-OSA trial (2024) showing an average AHI reduction of around 50 percent and significant CPAP-free symptom improvement. In 2026, NHS access to tirzepatide for OSA is still limited, mainly through specialist sleep and obesity clinics. Private prescription via UK pharmacies costs approximately £200-300 per month.

Bariatric surgery (gastric bypass or sleeve) remains an option for those with a BMI of 35 or above with significant OSA, resolving it in 60-80 percent of cases. NHS criteria and waiting times vary. The practical pathway is clear: anyone with OSA and a BMI over 30 should be offered weight management support. Tirzepatide has quickly become the most discussed new pharmacological option in both NHS and private clinics for OSA in 2026.

Hypoglossal nerve stimulation: NHS centres in 2026

For those who genuinely cannot tolerate CPAP, hypoglossal nerve stimulation (HNS) is a transformative option. A small device (like Inspire or Genio) is implanted under the skin of the chest, with a lead connected to the hypoglossal nerve in the neck. At night, it synchronises with your breathing pattern, gently stimulating the nerve to move the tongue forward and keep the airway open. NICE (IPG598) supports its use with standard clinical governance.

The list of UK NHS centres offering this in 2026 has expanded. It includes University College London Hospitals (UCLH), Imperial College Healthcare (Charing Cross Hospital), Royal Papworth Hospital in Cambridge, the Royal Brompton and Harefield in London, and Manchester University NHS Foundation Trust. More regional ENT centres are beginning to accept referrals.

Ideal candidates are adults aged 22 or over with moderate to severe OSA (AHI 15-65), typically with a BMI under 32-35. They must have failed or be intolerant of CPAP, and a drug-induced sleep endoscopy (DISE) must confirm they do not have complete concentric airway collapse.

Private cost is substantial, at £25,000-40,000. NHS access is expanding but still limited, with waiting lists at specialist centres. The results are good: 65-75 percent of well-selected patients see their AHI fall below 15, and 80 percent report being satisfied at two years. It’s a real, evidence-based alternative for the right UK patient.

Upper airway surgery for selected patients

Surgery plays a smaller but important role for patients with specific, identifiable anatomical issues. UK options via NHS ENT and maxillofacial teams include:

* Tonsillectomy: particularly effective in adults with markedly enlarged tonsils.
* Septoplasty: for severe nasal obstruction that prevents CPAP use.
* Uvulopalatopharyngoplasty (UPPP): an older procedure removing the uvula and parts of the soft palate; its use in the UK has declined due to variable success and painful recovery.
* Tongue base reduction: using radiofrequency or other techniques for patients with tongue-base obstruction identified on DISE.
* Maxillomandibular advancement (MMA): a major procedure that moves both jaws forward by 10-15 mm to enlarge the entire airway. It has a high success rate (60-90 percent AHI reduction) in selected patients but requires a demanding recovery. UK NHS centres performing this include the Royal London Hospital, Birmingham Dental Hospital, and John Radcliffe in Oxford.

Surgery suits patients with a clear anatomical narrowing where CPAP has failed. NICE recommends a multidisciplinary assessment beforehand. Most UK adults with OSA will not need surgery, but for the minority who do, it can be curative. Recovery varies: tonsillectomy takes 1-2 weeks, UPPP involves 2-3 weeks of significant pain, and MMA requires 4-6 weeks of recovery plus a year of subtle facial changes.

Lifestyle changes that help every UK adult with OSA

Regardless of your primary treatment, certain lifestyle measures are universally beneficial:

* Avoid alcohol within three hours of bedtime; it relaxes the upper airway muscles.
* Avoid sedative medications at night where possible; discuss alternatives with your GP.
* Sleep on your side if you have positional OSA.
* Aim to lose 10 percent of your body weight if your BMI is over 25. This is realistic in 4-6 months with diet, exercise, or GLP-1 medication.
* Treat nasal allergies and rhinitis with steroid sprays or saline rinses.
* Stop smoking, as it irritates the upper airway.
* Practice good sleep hygiene: consistent bedtime, a cool dark room, no screens an hour before bed, and no late caffeine.
* Remember the bigger picture: untreated OSA increases the risk of cardiovascular disease, stroke, atrial fibrillation, depression, and road traffic accidents. You must inform the DVLA if you have moderate or severe OSA with excessive daytime sleepiness.

Some 2026 wellness fads are best skipped. Mouth taping has no quality evidence for OSA and can be dangerous. Throat exercises may have a modest benefit for mild OSA but are not a replacement for proven therapy. Chin straps, anti-snoring nasal strips, CBD oil, and melatonin do not treat the underlying apnoea. A clear lifestyle plan, combined with CPAP or an evidence-based alternative, is what truly works.

Frequently Asked Questions

Do I have to wear CPAP forever?

Usually yes, for moderate to severe OSA, because the underlying anatomy and risk factors persist. Significant weight loss (20%+), bariatric surgery, hypoglossal nerve stimulation, or upper airway surgery can occasionally allow CPAP-free management. Most NHS sleep services advise continued use until a repeat sleep study confirms resolution. Modern APAP machines and masks make long-term use easier than a decade ago.

Can I get a mandibular advancement device on the NHS?

In some regions yes, particularly in Wales, parts of Scotland, and select NHS England dental sleep clinics, typically for mild OSA or CPAP failure. In many areas, you’ll need private fitting from a dental sleep medicine specialist, costing £350-800. NICE supports MADs for mild OSA and as an alternative when CPAP isn’t tolerated.

Can weight loss cure my sleep apnoea?

Mild and some moderate OSA can resolve with major weight loss (20%+ of body weight). A 10% loss reduces AHI by 25-30%. Severe OSA usually persists in a milder form. UK options include NHS weight management services, GLP-1 drugs like Wegovy and tirzepatide (newly licensed for OSA), and bariatric surgery. Continue CPAP until a repeat sleep study confirms resolution.

Is hypoglossal nerve stimulation available on the NHS?

Yes, at a growing number of centres including UCLH, Imperial (Charing Cross), Royal Papworth, Royal Brompton, and Manchester. Suitability requires moderate-severe OSA, a BMI under ~32-35, CPAP intolerance, and a clear DISE. Waiting lists exist. Private cost is £25,000-40,000. NICE supports its use.

Do I have to tell the DVLA about sleep apnoea?

Yes, if you have moderate or severe OSA causing excessive daytime sleepiness that affects driving. Rules differ for Group 1 (car) and Group 2 (HGV/bus) licences. You must declare via DVLA form SL1 or SL1V. Driving must stop until sleepiness is controlled with treatment. It’s not an automatic ban, but failure to declare is a criminal offence and invalidates insurance.

What is tirzepatide (Mounjaro) and is it really licensed for sleep apnoea?

Tirzepatide is a weekly GIP/GLP-1 agonist injection for weight loss and diabetes. In 2025, the UK MHRA approved it specifically for moderate to severe OSA in adults with obesity, based on a 2024 trial showing ~50% AHI reduction. NHS access in 2026 is limited, mainly via specialists. Private cost is ~£200-300 per month.

This article is informational only and does not replace personalised advice from your GP, pharmacist, or another qualified healthcare professional.